New Study Reveals – Patients with Plaque Psoriasis Treated with JNJ-2113 Maintain Skin Clearance Up to One YearÂ
Johnson & Johnson recently announced the first data from their FRONTIER 2 clinical trial which evaluated JNJ-2113. This is the first and only investigational targeted oral peptide designed to block